Health News Releases

  • Today August 23
ABB's mobile and autonomous YuMi® laboratory robot concept will be designed to work alongside medic
October 10, 2019 11:02
ABB Demonstrates Concept of Mobile Laboratory Robot for Hospital of the Future
ABB today opened its first global healthcare research hub on the Texas Medical Center (TMC) campus, in Houston, Texas - showcasing a number of concept technologies, including a mobile YuMi® robot, whi
October 10, 2019 10:48
Samsung Bioepis Presents Real-world Data of BENEPALI™ (etanercept) in Patients with Psoriasis at European Academy of Dermatology and Venereology (EADV) Congress
Samsung Bioepis Co., Ltd. today announced real-world data of BENEPALI™ in patients with moderate to severe psoriasis from the British Association of Dermatologists Biologics and Immunomodulators Regis
October 04, 2019 19:25
MPEG LA Announces Peer Reviewed Article Featured in Nucleic Acid Therapeutics
World technology licensing leader MPEG LA today announced publication of a peer reviewed article in the October 2019 issue of Nucleic Acid Therapeutics on MPEG LA’s proprietary Increscent Therapeutics
October 01, 2019 16:37
New data reinforces benefits of Spiolto® Respimat® in improving patient outcomes
Boehringer Ingelheim announced Spiolto® (tiotropium/olodaterol) Respimat® data being presented at the European Respiratory Society (ERS) 2019 Congress. The results show the benefits of tiotropium/olod
October 01, 2019 16:29
Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio
Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refrac
October 01, 2019 12:05
Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis
Octapharma announced today that the European Medicines Agency has authorised an updated Summary of Product Characteristics (SmPC) for Nuwiq® that includes information on personalised prophylaxis in pa
September 30, 2019 15:43
INBUILD® meets primary endpoint - study evaluated nintedanib in patients across a range of progressive fibrosing interstitial lung diseases[1]
Boehringer Ingelheim announced today that in the Phase III INBUILD® trial nintedanib slowed lung function decline by 57% across the overall study population, as assessed by the annual rate of decline
September 27, 2019 11:13
Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar Candidate, at the European Society for Medical Oncology (ESMO) 2019 Congress
Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference bevacizumab in patients wi
September 27, 2019 10:47
New Data Presented at World Sleep Congress Demonstrate Early Signs of Efficacy for TAK-925, a Selective Orexin Type-2 Receptor (OX2R) Agonist, in Patients with Narcolepsy Type 1
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) announced results of a Phase 1 clinical proof of concept study of the novel investigational compound TAK-925, a selective orexin ty
September 26, 2019 11:13
First Head-to-Head Biologic Study in Ulcerative Colitis Published in The New England Journal of Medicine Highlights Benefit of Vedolizumab vs. Adalimumab
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the VARSITY study, which demonstrated the superiority of the gut-selective biologic vedolizuma
September 25, 2019 09:12
New England Journal of Medicine Publishes Results of a Phase 2 Trial Evaluating Takeda’s TAK-620 (Maribavir) as a Potential Treatment of Cytomegalovirus (CMV) Infection
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the New England Journal of Medicine has published results of a Phase 2, randomised, 12-week, open-label study
September 24, 2019 10:28
Study Investigates the Ability of Masimo Noninvasive, Continuous Hemoglobin (SpHb®) to Provide Earlier Indication of Anemia and the Impact of Anemia on Patient Outcomes
Masimo (NASDAQ: MASI) announced today that in a study published in Injury, researchers used Masimo SpHb® - noninvasive, continuous hemoglobin monitoring - to investigate possible delays in the detecti
September 23, 2019 16:09
Patient Safety Leaders and Advocates Discuss Solutions to Eliminate Preventable Patient Deaths
On the same day the World Health Organization (WHO) designated World Patient Safety Day, The Patient Safety Movement Foundation’s (PSMF) Midyear Planning Meeting (MYPM) brought together more than a hu
September 23, 2019 14:08
Takeda Recognized in the 2019 Dow Jones Sustainability World Index
Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502/NYSE:TAK) today announced that it has been named in the 2019 Dow Jones Sustainability World Index, achieving more than double the average o
September 23, 2019 13:56
Larger, healthier, more plentiful — Study proves House Wellness Foods’ Feed LP20® improves stock at the cellular level.
Eons ago, the progress of humankind was thrust forward with the development of farming. Today that progress is challenged simultaneously by climatic and socioeconomic forces, and the future hangs in t
September 23, 2019 13:10
Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases
Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with
September 20, 2019 13:55
Taiwan: Rising Importance of Proton Therapy and a Fortress for Cancer Treatment
There is no place like Taiwan where medical services are readily accessible with quality and efficiency, attracting nearly 500,000 patients worldwide annually and attention from dominant medical devic
September 20, 2019 11:15
Solasia Announces Patient Registration Reached Target Number of Cases for Darinaparsin Phase 2 Pivotal Study for T-Cell Lymphoma
Solasia Pharma K.K. (TSE:4597, Headquarters: Tokyo, President & CEO: Yoshihiro Arai, hereinafter “Solasia”), a specialty pharmaceutical company based in Asia, today announced that patient registration
September 20, 2019 09:05
Consistent cardiovascular benefits shown with empagliflozin treatment regardless of the number of controlled cardiovascular risk factors
Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced results of a post-hoc analysis of the landmark EMPA-REG OUTCOME® trial that were presented at the 55th Annual Meeting of the
September 19, 2019 10:23
Three Hospital Systems Earn Five-Star Award from Patient Safety Movement Foundation
On the first World Patient Safety Day, the Patient Safety Movement Foundation (PSMF) announces that it has awarded Dignity Health, MedStar Health and the UPMC with its five-star award for making commi
September 16, 2019 13:50
Hansoh Pharma and Atomwise Launch Strategic AI Drug Discovery Collaboration for Multiple Therapeutic Areas
Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”), a leading biopharmaceutical company in China, and Atomwise, Inc. (“Atomwise”), the leader in artificial intelligence (AI) for drug discov
September 16, 2019 09:26
Aptorum Group Has Initiated IND-Enabling Studies For Its ALS-4 Small Molecule Candidate For The Treatment Of Infections Caused By Staphylococcus Aureus Including MRSA
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces that it has initiat
September 16, 2019 09:19
Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces the development of
September 10, 2019 09:04
Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Celgene Corporation (NASDAQ:CELG) today announced it will present 13 scientific abstracts, including new analyses from the Phase 3 ozanimod clinical development program in adults with relapsing forms
September 09, 2019 11:03
Walgreens Boots Alliance Appoints Global Chief Information Officer
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced Francesco Tinto was named global chief information officer (CIO) and senior vice president at the company, which ranks #17 on the Fortune 5
25 per page50 per page75 per page100 per page